Postmenopausal osteoporosis is the most common bone disease, associated with low bone
mineral density (BMD) and pathological fractures which lead to significant morbidity. It is …

Antiresorptive agents, used in the treatment of osteoporosis, inhibit either osteoclast
formation or function. However, with these approaches, osteoblast activity is also reduced …

The application of bioisosteres in drug discovery is a well-established design concept that
has demonstrated utility as an approach to solving a range of problems that affect candidate …

Abstract Osteoporosis, a “silent disease,” is often unrecognized until fracture. Lifestyle
modification with nutritional counseling is recommended during menopausal transition …

Остеопороз (ОП)–широко распространенное хроническое прогрессирующее
метаболическое системное заболевание скелета, которое характеризуется …

Cathepsin K is a major drug target for osteoporosis and related-bone disorders. Using a
combination of virtual combinatorial chemistry, QSAR modeling, and molecular docking …

Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility
and an increased risk of fracture. It occurs due to an imbalance between bone resorption …

Although several methods have been used in bone regeneration medicine, current methods
still have many limitations. The tissue used for autogenous bone graft is limited and allograft …

Highlights•Selective cathepsin K inhibition inhibits bone resorption in clinical and preclinical
studies.•Wnt signaling promotes bone formation.•Blockade of Wnt inhibitors increases bone …

Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common
among postmenopausal women. Currently, almost all pharmacological agents for …